|
Limited R&D investment in the
region has resulted in high
dependence on imported
pharmaceutical products.
Due to higher than average
growth of population in most
sub-markets, the demand for
imported pharmaceutical products
has been growing at nearly
double digits in recent years.
MENA patients are highly brand
conscious, with 50% of the
market based on private sales.
Cost containment measures in the
institutional sector has opened
up the market for cost-effective
generics. |
|
|
|
